BSE Fundamental Analysis - Balance Sheet & Share Holding Pattern

ANGLIFESCIENCESINDIA01 Jan 1900

₹

0.00 (0.00%)

Lowest Today

Highest Today

Prev. Close

Today’s Open

52 Week High

52 Week Low

BUY

SELL

To Invest in

ANGLIFESCIENCESINDIA01 Jan 1900

₹

0.00 (0.00%)

OverviewFundamentals

Corporate action

Peer comparison

Income Sheet

Balance sheet

Cash flow

Share holding

About Us

Corporate Action

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

All

Dividends

Bonus

Splits

Others

Ex-Date	Type	Description	Record Date	Ratio
25-Oct-2021	D	ANG Lifesciences India Ltd has informed BSE that the Board of Directors of the Company at its meeting held on October 25, 2021, inter alia, has declared an Interim Dividend of Rs. 1/- per Equity Shares (10% on the face value of Rs. 10/- each). This is the first Interim Dividend declared by the Board for the Financial Year 2021-22.	02-Nov-2021
01-Jul-2022	B	1:4 Bonus Issue of Equity Shares Trading Members of the Exchange are hereby informed that, ANG Lifesciences India Limited has fixed Record Date for the purpose of Bonus Issue. The transactions in the equity shares of the company would be on an ex-bonus basis with effect from the under mentioned date : DEMATERIALISED SECURITIES - ROLLING SETTLEMENT SEGMENT COMPANY NAME & CODE ANG Lifesciences India Limited (540694) RECORD DATE 14.07.2022 PURPOSE Issue of 1 (One) Bonus equity shares of Rs.10/- each for every 4 (Four) existing equity share of Rs.10/- each held. Ex-Bonus basis from Date & Sett. No. 13/07/2022 DR-073/2022-2023 (As Per BSE Notice Dated on 08.07.2022)	14-Jul-2022	1:4
14-Sep-2021	B	1:1 Bonus Issue of Equity Shares Trading Members of the Exchange are hereby informed that, ANG Lifesciences India Limited has fixed the record date for the purpose of Bonus Issue. The transactions in the equity shares of the company would be on an ex-bonus basis with effect from the under mentioned date. DEMATERIALISED SECURITIES - ROLLING SETTLEMENT SEGMENT COMPANY NAME & CODE ANG Lifesciences India Limited (540694) RECORD DATE 23/09/2021 PURPOSE Issue of 1 (One) Bonus equity share of Rs.10/- each for every 1 (One) existing equity share of Rs.10/- each held. Ex-Bonus basis from Date & Sett. No. 22/09/2021 DR-120/2021-2022 Trading Members are requested to note the change in the market lot of ANG Lifesciences India Limited (540694) pursuant to the Bonus Issue of equity shares as given below, which will be effective from Wednesday, September 22, 2021: Scrip Code 540694 Scrip Name ANG Lifesciences India Limited Current Market Lot 1600 Revised Market Lot 3200 (As Per BSE Notice Dated on 14.09.2021)	23-Sep-2021	1:1
07-Feb-2024	BC	ANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2024 inter alia to consider and approve 1. The Unaudited Standalone & Consol	14-Feb-2024
06-Nov-2023	BC	Quarterly Results Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation, 2015, this to submit that the Board of Directors	14-Nov-2023
14-Oct-2023	BC	In pursuant to Reg 30 of SEBI LODR, 2015, we hereby inform you that Mr. Neeraj Gupta tendered his resignation from the position of Chief Financial Officer due to his personal reason.	14-Oct-2023
11-Oct-2023	BC	In pursuant to Regulation 30 of SEBI LODR 2015 Mr. Rohit Mittal has appointed as Additional Director in the capacity Non Executive Non Independent Director Pursuant to Reg 30 of SEBI LODR, 2015, t	10-Oct-2023
05-Sep-2023	BC	Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, We hereby inform you that the Board of Directors of the Company in its meeting held on today	30-Sep-2023

No Rights has been declared by ANGLIFESCIENCESINDIA

Book Closure

Record Date	Split Date	Purpose
14-Feb-2024	-	ANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2024 inter alia to consider and approve 1. The Unaudited Standalone & Consol
14-Nov-2023	-	Quarterly Results Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation, 2015, this to submit that the Board of Directors
14-Oct-2023	-	In pursuant to Reg 30 of SEBI LODR, 2015, we hereby inform you that Mr. Neeraj Gupta tendered his resignation from the position of Chief Financial Officer due to his personal reason.
10-Oct-2023	-	In pursuant to Regulation 30 of SEBI LODR 2015 Mr. Rohit Mittal has appointed as Additional Director in the capacity Non Executive Non Independent Director Pursuant to Reg 30 of SEBI LODR, 2015, t
30-Sep-2023	-	Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, We hereby inform you that the Board of Directors of the Company in its meeting held on today

Peer Comparison

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Scrip Name	Price	Daily Change	M.Cap (Cr)	1 Year Returns %	P/E (TTM)	PB Ratio
Lupin Ltd ₹1,654.10(+16.65/1.02%)	1,654.10	+16.65	74,626.80	131.02	36.21	3.87
Ipca Laboratories Ltd ₹1,345.40(+11.40/0.85%)	1,345.40	+11.40	33,844.14	88.32	61.44	5.45
J B Chemicals & Pharmaceuticals Ltd ₹1,901.30(-5.35/-0.28%)	1,901.30	-5.35	29,590.22	83.33	58.44	11.03
Sanofi India Ltd ₹8,330.00(+52.50/0.63%)	8,330.00	+52.50	19,063.08	52.52	32.30	18.78
IOL Chemicals & Pharmaceuticals Ltd ₹397.55(+1.05/0.26%)	397.55	+1.05	2,327.67	-3.19	13.49	1.46

Income Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Gross Sales	17.10	29.58	50.61	31.88	45.17	58.39
Excise Duty	0.00	0.00	0.00	0.00	0.00	0.00
Net Sales	17.10	29.58	50.61	31.88	45.17	58.39
Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
Other Income	-0.09	0.33	0.34	9.20	0.32	0.20
Total Income	17.01	29.91	50.95	41.08	45.49	58.60
Total Expenditure	18.82	28.26	44.94	43.48	43.03	49.15
PBIDT	-1.80	1.65	6.01	-2.40	2.46	9.44
Interest	1.99	1.96	1.94	1.11	2.84	3.20
PBDT	-3.80	-0.31	4.07	-3.51	-0.38	6.24
Depreciation	2.02	1.97	1.94	2.82	1.92	1.90
Tax	-0.47	-0.35	0.82	-1.15	-0.63	1.52
Deferred Tax	-0.75	0.12	-0.28	-0.15	-0.07	0.20
Reported Profit After Tax	-4.59	-2.05	1.60	-5.03	-1.60	2.62
Extra-ordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
Adjusted Profit After Extra-ordinary item	-4.59	-2.05	1.60	-5.03	-1.60	2.62

EPS (Unit Curr.)	-3.51	-1.53	1.28	-3.95	-1.22	2.19
EPS (Adj) (Unit Curr.)	-3.51	-1.53	1.28	-3.95	-1.22	2.19
Calculated EPS (Unit Curr.)	-3.52	-1.57	1.22	-3.85	-1.22	2.02
Calculated EPS (Adj) (Unit Curr.)	-3.52	-1.57	1.22	-3.85	-1.22	2.02
Calculated EPS (Ann.) (Unit Curr.)	-14.06	-6.28	4.89	-15.41	-4.89	8.09
Calculated EPS (Adj) (Ann.) (Unit Curr.)	-14.06	-6.28	4.89	-15.41	-4.89	8.09
Book Value (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend (%)	0.00	0.00	0.00	0.00	0.00	0.00
Equity	13.06	13.06	13.06	13.06	13.06	12.96
Reserve & Surplus	0.00	0.00	0.00	0.00	0.00	0.00
Face Value	10.00	10.00	10.00	10.00	10.00	10.00

Public Shareholding (No. Of Shares)	0.00	0.00	0.00	0.00	0.00	0.00
Public Shareholding (% in Equity)	0.00	0.00	0.00	0.00	0.00	0.00

Pledged/Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

Non Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

PBIDTM(%)	-10.53	5.58	11.88	-7.53	5.45	16.17
PBDTM(%)	-22.22	-1.05	8.04	-11.01	-0.84	10.69
PATM(%)	-26.84	-6.93	3.16	-15.78	-3.54	4.49

Column	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Gross Sales	18.55	33.26	56.46	39.44	46.93	59.82
Excise Duty	0.00	0.00	0.00	0.00	0.00	0.00
Net Sales	18.55	33.26	56.46	39.44	46.93	59.82
Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
Other Income	-0.03	0.22	0.32	9.23	0.24	0.16
Total Income	18.52	33.49	56.78	48.67	47.16	59.98
Total Expenditure	20.46	31.60	49.92	49.72	44.17	50.18
PBIDT	-1.94	1.88	6.86	-1.05	2.99	9.81
Interest	2.51	2.29	2.31	1.65	3.47	3.31
PBDT	-4.45	-0.41	4.55	-2.70	-0.47	6.50
Depreciation	1.91	2.22	2.19	3.03	2.13	2.11
Minority Interest Before NP	0.00	0.00	0.00	0.00	0.00	0.00
Tax	-0.47	-0.35	0.82	-1.15	-0.63	1.52
Deferred Tax	0.03	0.03	-0.21	0.03	-0.20	0.24
Reported Profit After Tax	-5.93	-2.32	1.75	-4.61	-1.78	2.63
Minority Interest After NP	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit after Minority Interest	-5.93	-2.32	1.75	-4.61	-1.78	2.63

Extra-ordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
Adjusted Profit After Extra-ordinary item	-5.93	-2.32	1.75	-4.61	-1.78	2.63

EPS (Unit Curr.)	-4.52	-1.74	1.41	-3.63	-1.36	2.20
Book Value (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend (%)	0.00	0.00	0.00	0.00	0.00	0.00
Equity	13.06	13.06	13.06	13.06	13.06	12.96

Public Shareholding (Number)	0.00	0.00	0.00	0.00	0.00	0.00
Public Shareholding (%)	0.00	0.00	0.00	0.00	0.00	0.00

Pledged/Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

Non Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

PBIDTM(%)	-10.46	5.65	12.15	-2.66	6.37	16.40
PBDTM(%)	-23.99	-1.23	8.06	-6.85	-1.00	10.87
PATM(%)	-31.97	-6.98	3.10	-11.69	-3.79	4.40

Balance Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18
SOURCES OF FUNDS :
Share Capital	13.06	10.37	5.18	5.18	5.18	5.18
Reserves Total	67.79	68.42	34.72	29.37	23.58	17.99
Equity Share Warrants	0.00	0.00	0.00	0.00	0.00	0.00
Equity Application Money	4.69	4.69	1.45	0.00	0.00	0.00
Total Shareholders Funds	85.54	83.48	41.35	34.55	28.76	23.17
Secured Loans	48.78	52.75	38.08	18.03	19.55	15.27
Unsecured Loans	6.78	8.24	4.32	2.80	2.35	2.15
Total Debt	55.56	60.99	42.40	20.83	21.90	17.42
Total Liabilities	141.10	144.47	83.75	55.38	50.66	40.59
APPLICATION OF FUNDS :
Gross Block	107.94	103.12	37.57	33.73	32.24	20.00
Less : Accumulated Depreciation	29.26	20.80	15.68	12.79	11.65	10.52
Less:Impairment of Assets	0.00	0.00	0.00	0.00	0.00	0.00
Net Block	78.68	82.32	21.89	20.94	20.59	9.48
Lease Adjustment	0.00	0.00	0.00	0.00	0.00	0.00
Capital Work in Progress	0.00	0.00	0.40	0.23	0.16	11.57
Producing Properties	0.00	0.00	0.00	0.00	0.00	0.00
Investments	3.52	3.52	0.02	0.02	0.02	0.02
Current Assets, Loans & Advances	0.00	0.00	0.00	0.00	0.00	0.00
Inventories	37.39	29.17	19.26	10.00	6.54	7.74
Sundry Debtors	78.11	98.99	58.78	46.06	41.75	32.15
Cash and Bank	6.05	6.59	0.11	3.60	4.37	1.48
Loans and Advances	48.35	46.82	33.74	13.00	7.30	5.50
Total Current Assets	169.91	181.56	111.89	72.67	59.96	46.87
Less : Current Liabilities and Provisions	0.00	0.00	0.00	0.00	0.00	0.00
Current Liabilities	85.43	85.84	50.37	32.91	24.58	24.66
Provisions	17.74	19.09	5.02	2.40	2.20	1.04
Total Current Liabilities	103.17	104.93	55.38	35.31	26.78	25.70
Net Current Assets	66.74	76.63	56.51	37.36	33.18	21.17
Miscellaneous Expenses not written off	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Assets	1.51	1.82	0.41	0.05	0.00	0.12
Deferred Tax Liability	3.00	2.45	0.00	0.36	0.40	0.49
Net Deferred Tax	-1.49	-0.63	0.41	-0.31	-0.40	-0.37
Total Assets	147.45	161.84	79.23	58.24	53.56	41.86
Contingent Liabilities	16.63	20.30	15.87	9.32	6.45	0.00

Cash Flow

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

PARTICULARS	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019
Cash and Cash Equivalents at Beginning of the year	0.29	0.11	0.27	4.37	1.48
Net Cash from Operating Activities	26.01	27.39	-11.18	4.83	7.46
Net Cash Used In Investing Activities	-9.35	-42.50	-7.79	-1.66	-0.77
Net Cash Used In Financing Activities	-16.75	15.29	18.81	-3.95	-3.80
Net Inc./Dec In Cash And Cash Equivalents	-0.08	0.17	-0.16	-0.77	2.89
Cash And Cash Equivalents At End Of The Year	0.20	0.29	0.11	3.60	4.37

Share Holding

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Promoter Shareholding

70.60%

FII Shareholding

0.00%

DII Shareholding

0.00%

Public Shareholding

29.40%

**Promoter pledged shareholding 70.60%

About ANG Lifesciences India Ltd

ANG Lifesciences India Ltd is in the Pharmaceuticals sector, having a market capitalization of Rs. 75.09 crores. It has reported a sales of Rs. 17.1 crores and a net profit of Rs. -4.59 crores for the quarter ended December 2018. The company management includes , Rajesh Gupta,Saruchi Gupta,Sukhpal Singh,Sudesh Kumari,Pawanjit Singh,Chetna,Renu (ANG Lifesciences India Ltd) among others.

Chairman

Registered office

Darbara Complex SCO 113 I Flr,Dist. Shopping Centre B Block,Amritsar,Punjab,143001

FAX :

Background

Incorporation Year2006

Face Value₹10

Market Lot1

How to buy shares on nse?

To buy shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified

What is the share price today?

The shares price on nse is Rs.0 today.

What is the market cap of shares on ?

The company has a market capitalization of Rs.0.00Cr

What is the PE & PB ratio of shares ?

PE is 0 and PB is 0

What is the 52 Week High and Low of shares?

stock price high: Rs.0 stock price low: Rs.0